drugset

drugset / Trial / NCT02061670

Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma

NCT02061670 ↗

Phase 2 Completed 55 enrolled Circassia Limited Adiga Life Sciences, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.

Timeline

Start: 2014-01
Primary completion: 2014-10
Completion: 2014-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ragweed-SPIRE	Unknown	—	Other

Indications